Current P SYCHIATRY

Total Page:16

File Type:pdf, Size:1020Kb

Current P SYCHIATRY Primary care update Current p SYCHIATRY Hypertension Pitfalls to prescribing for patients with high blood pressure Edward Onusko, MD Assistant professor of family medicine University of Cincinnati College of Medicine Cincinnati, OH Chronic psychiatric disorders go hand-in-hand with risk factors for elevated blood pressure. Here are diagnostic and treatment strategies to help you detect comorbid hypertension and keep blood pressure in control. oughly 50 million adult Americans have hyperten- Causes of hypertension in mental illness R sion.1 Chances are some of them are—or soon will The Joint National Committee on Prevention, Detection, be—under your care. Evaluation, and Treatment of High Blood Pressure defines Hypertension is common among patients with psychi- elevated blood pressure as ≥ 140 mm Hg systolic and/or 90 atric disorders, particularly in those with chronic mental con- mm Hg diastolic. The diagnosis of hypertension should be ditions.2 Medication-associated weight gain and other reac- based on the average of two or more blood pressure readings tions to psychotropics, drug-drug interactions, lack of exer- at each of two or more visits after initial screening. cise, adverse dietary habits, and pre-existing medical condi- All patients with elevated blood pressure have an under- tions all predispose psychiatric patients to hypertension. lying physiologic abnormality that is causing their hyperten- Yet hypertension often goes undetected in psychiatric sion. The disorder falls within the following two categories: patients. Hypertension many times is asymptomatic—about • essential hypertension, emanating from an unknown 50% of all people with the disorder don’t even know they have cause it.3 Some symptoms of uncontrolled hypertension—fatigue, • secondary hypertension, resulting from an underlying, headache, palpitations, and dizziness—are also associated discoverable, often treatable cause. with many psychiatric disorders. As a result, psychiatrists may Researchers have speculated that certain psychiatric dis- attempt to manage the symptoms but miss the hypertension. orders might cause, or be risk factors for, hypertension. Psychiatrists need to be alert for hypertension, either as a Anxiety or panic disorders have been associated with acute possible contributing factor to a mental disorder or as a (and perhaps chronic) blood pressure elevations.2 Some potential side effect of a psychiatric disorder or treatment. research suggests that patients with alexithymia are at risk for The following diagnostic and treatment strategies will help developing hypertension.4 you detect and manage this common condition. Other studies suggest that hypertensive patients with VOL. 1, NO. 9/SEPTEMBER 2002 53 H ypertension certain psychological disorders (e.g., depression) or social selective serotonin reuptake inhibitors. Use of carbamazepine factors (e.g., substance abuse) are less likely than nonaffected with calcium-channel blockers can elevate carbamazapine patients to self-report the presence of hypertension and less levels and diminish the effectiveness of the calcium-channel likely to receive medical attention for it.5 blocker. Psychiatric drugs also may affect blood pressure by one of two mechanisms: Symptoms, complications of high blood pressure • Pharmacodynamic—direct effects at the site of action Symptoms that may be associated with high blood pressure (e.g., receptors) via physiologic mechanisms (Table 1). include headaches, dizziness, lightheadedness, fatigue, palpi- For example, amphetamines act directly on the sympa- tations, and chest discomfort. Patients may also experience thetic nervous system to elevate blood pressure. symptoms secondary to end-organ damage (e.g., shortness of breath from congestive heart Table 1 failure). POSSIBLE PHARMACODYNAMIC EFFECTS Most people, however, experi- OF PSYCHIATRIC MEDICATIONS ON BLOOD PRESSURE ence no symptoms when their blood pressure is elevated. This Psychiatric medication Effect on blood pressure is one reason most people with Amphetamines hypertension do not adequately Benzodiazepines Withdrawal may cause control their blood pressure. Tricyclic antidepressants or (postural hypotension or Aside from the long-term supine hypertension) end-organ damage caused by persistently elevated blood pres- Methylphenidate sure, hypertension also has been Monoamine oxidase inhibitors may precipitate an acute found to cause psychiatric disor- hypertensive crisis, especially with ders, though not directly. For foods with high tyramine content example, post-MI depression is (e.g., red wines, aged cheeses) well-recognized. Hypertension Lithium via direct effect on renal may also cause multi-infarct concentrating ability dementia with resultant depression, paranoia, or other Venlafaxine dose-related, <1% incidence psychotic features. Antipsychotics The psychological burden (both typical and atypical) of having chronic and usually incurable (though controllable) • Pharmacokinetic—indirect effects on blood pressure via hypertension may worsen depression or anxiety disorders. drug/drug interactions that alter the absorption, distrib- Patients with a chronic psychiatric illness generally have a ution, metabolism, or clearance of antihypertensive higher incidence of chronic medical problems. medications. Thiazide diuretics, angiotensin-converting Likewise, patients with chronic medical disorders have a enzyme (ACE) inhibitors, and salt intake restrictions higher incidence of psychiatric complaints.6 can raise lithium levels. The calcium-channel blockers verapamil and diltiazem can unpredictably increase or Patient evaluation decrease lithium levels, but the combination generally is When evaluating the patient with elevated blood pressure, it safe. Verapamil also raises tricyclic antidepressant levels. is important to: Monoamine oxidase inhibitors (MAOIs) used in tandem • detect and confirm hypertension with the antihypertensive reserpine can cause hypomania. • detect target-organ disease (e.g., renal damage or Beta-blocker levels are increased when used in concert with congestive heart failure) continued on page 57 54 Current VOL. 1, NO. 9 / SEPTEMBER 2002 p SYCHIATRY Current p SYCHIATRY continued from page 54 Table 2 ANTIHYPERTENSIVE MEDICATIONS AND SIDE EFFECTS Antihypertensive class Agent(s) Possible associated psychiatric symptoms Beta-adrenergic blocking agents Propranolol, atenolol, Fatigue, depression, psychosis, delirium, anxiety, metoprolol, others sexual dysfunction, nightmares, hallucinations* Angiotensin-converting enzyme Captopril, enalapril, Mania, anxiety, hallucinations (ACE) inhibitors lisinopril, ramipril, others Angiotensin II receptor blockers Losartan, valsartan, Probably same as ACE inhibitors (ARBs or AIIAs) others Diuretics Hydrochlorothiazide, Sexual dysfunction, depression furosemide Calcium-channel blockers Nifedipine, verapamil, Dizziness, headache, flushing, tachycardia, diltiazem depression Alpha-adrenergic blockers Prazosin, terazosin, Syncope, dizziness and vertigo, palpitations, doxazosin drowsiness, weakness, confusion Central alpha-adrenergic agonists Clonidine, methyldopa Drowsiness, sedation, fatigue, depression, impotence, delirium, psychosis, nightmares, amnesia Direct vasodilators Hydralazine, minoxidil Tachycardia, headache, dizziness Peripheral adrenergic Reserpine, guanadrel Drowsiness, depression, nightmares, neuron antagonists tardive dyskinesia *May occur with ophthalmic preparations • identify other cardiovascular risk factors (e.g., diabetes All other factors being equal, the sixth report of the Joint mellitus, hyperlipidemia, obesity) National Committee on Prevention, Detection, Evaluation • identify secondary causes of hypertension, such as and Treatment of High Blood Pressure (JNC-VI) recom- endocrine abnormalities (e.g., hyperaldosteronism, mends initial treatment with a diuretic or beta-blocker. thyroid disorders), kidney disease, obstructive sleep These classes of drugs have been shown to significantly apnea, and response to medications. reduce overall hypertension-related mortality. A thorough history and physical examination should be Most patients with hypertension—particu- performed to assess these four areas. Routine laboratory test- larly the elderly, patients with diabetes melli- ing for the hypertensive patient should include a urinalysis, a tus, and those with renal disease—will complete blood count, an assessment of blood chemistries need two or more agents to control (potassium, sodium, creatinine, fasting glucose, fasting lipid their blood pressure. Avoid prescrib- profile), and a 12-lead electrocardiogram. ing agents that may worsen an existing condition (e.g., beta-block- Treating hypertension ers may worsen bronchospasm in Many medications are used to treat hypertension. Most class- patients with asthma). Use agents that may help improve es of antihypertensive agents have been shown to be about comorbid conditions (e.g., beta-blockers have been shown to equally effective in lowering blood pressure. reduce mortality in patients with previous MI). VOL. 1, NO. 9/SEPTEMBER 2002 57 H ypertension Box As more is learned about genetic and other causes of THE FUTURE OF HYPERTENSION TREATMENT hypertension, more-effective treatments for hypertension could become available (Box). he Joint National Committee on Detection, Evaluation, Tand Treatment of High Blood Pressure (JNC), which Treating high-risk groups has issued six previous reports on hypertension control, Special considerations apply to two patient groups with a is expected to issue
Recommended publications
  • The In¯Uence of Medication on Erectile Function
    International Journal of Impotence Research (1997) 9, 17±26 ß 1997 Stockton Press All rights reserved 0955-9930/97 $12.00 The in¯uence of medication on erectile function W Meinhardt1, RF Kropman2, P Vermeij3, AAB Lycklama aÁ Nijeholt4 and J Zwartendijk4 1Department of Urology, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands; 2Department of Urology, Leyenburg Hospital, Leyweg 275, 2545 CH The Hague, The Netherlands; 3Pharmacy; and 4Department of Urology, Leiden University Hospital, P.O. Box 9600, 2300 RC Leiden, The Netherlands Keywords: impotence; side-effect; antipsychotic; antihypertensive; physiology; erectile function Introduction stopped their antihypertensive treatment over a ®ve year period, because of side-effects on sexual function.5 In the drug registration procedures sexual Several physiological mechanisms are involved in function is not a major issue. This means that erectile function. A negative in¯uence of prescrip- knowledge of the problem is mainly dependent on tion-drugs on these mechanisms will not always case reports and the lists from side effect registries.6±8 come to the attention of the clinician, whereas a Another way of looking at the problem is drug causing priapism will rarely escape the atten- combining available data on mechanisms of action tion. of drugs with the knowledge of the physiological When erectile function is in¯uenced in a negative mechanisms involved in erectile function. The way compensation may occur. For example, age- advantage of this approach is that remedies may related penile sensory disorders may be compen- evolve from it. sated for by extra stimulation.1 Diminished in¯ux of In this paper we will discuss the subject in the blood will lead to a slower onset of the erection, but following order: may be accepted.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • WO 2013/169741 Al 14 November 2013 (14.11.2013) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2013/169741 Al 14 November 2013 (14.11.2013) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/401 (2006.01) A61P 9/12 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/405 (2006.01) A61P 25/00 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 31/7048 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, PCT/US20 13/039904 KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, (22) International Filing Date: ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, 7 May 2013 (07.05.2013) NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, (25) Filing Language: English TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, (26) Publication Language: English ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/644,134 8 May 2012 (08.05.2012) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, (72) Inventors; and UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (71) Applicants : STEIN, Emily A.
    [Show full text]
  • Psychiatric Medications in Behavioral Healthcarev5
    Copyright © The University of South Florida, 2012 Psychiatric Medications in Behavioral Healthcare An Important Notice None of the pages in this tutorial are meant to be a replacement for professional help. The science of medicine is constantly changing, and these changes alter treatment and drug therapies as a result of what is learned through research and clinical experience. The author has relied on resources believed to be reliable at the time material was developed. However, there is always the possibility of human error or changes in medical science and neither the authors nor the University of South Florida can guarantee that all the information in this program is in every respect accurate or complete and they are not responsible for any errors or omissions or for the results obtained from the use of such information. Each person that reads this program is encouraged to confirm the information with other sources and understand that it not be interpreted as medical or professional advice. All medical information needs to be carefully reviewed with a health care provider. Course Objectives At the completion of this program participants should be able to: • Identify at 5 categories of medications used to treat the symptoms of psychiatric disorders, the therapeutic effects of medications in each category, and the side effects associated with medications in each category. • Identify at least 5 medications and the benefits of those medications as compared to the medications. • Identify at least 5 reasons that a person may stop taking medications or not take medications as prescribed. • Demonstrate your learned understanding of psychiatric medications by passing the combined post‐ tests.
    [Show full text]
  • The Psychoactive Effects of Psychiatric Medication: the Elephant in the Room
    Journal of Psychoactive Drugs, 45 (5), 409–415, 2013 Published with license by Taylor & Francis ISSN: 0279-1072 print / 2159-9777 online DOI: 10.1080/02791072.2013.845328 The Psychoactive Effects of Psychiatric Medication: The Elephant in the Room Joanna Moncrieff, M.B.B.S.a; David Cohenb & Sally Porterc Abstract —The psychoactive effects of psychiatric medications have been obscured by the presump- tion that these medications have disease-specific actions. Exploiting the parallels with the psychoactive effects and uses of recreational substances helps to highlight the psychoactive properties of psychi- atric medications and their impact on people with psychiatric problems. We discuss how psychoactive effects produced by different drugs prescribed in psychiatric practice might modify various disturb- ing and distressing symptoms, and we also consider the costs of these psychoactive effects on the mental well-being of the user. We examine the issue of dependence, and the need for support for peo- ple wishing to withdraw from psychiatric medication. We consider how the reality of psychoactive effects undermines the idea that psychiatric drugs work by targeting underlying disease processes, since psychoactive effects can themselves directly modify mental and behavioral symptoms and thus affect the results of placebo-controlled trials. These effects and their impact also raise questions about the validity and importance of modern diagnosis systems. Extensive research is needed to clarify the range of acute and longer-term mental, behavioral, and physical effects induced by psychiatric drugs, both during and after consumption and withdrawal, to enable users and prescribers to exploit their psychoactive effects judiciously in a safe and more informed manner.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2012/0115729 A1 Qin Et Al
    US 201201.15729A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0115729 A1 Qin et al. (43) Pub. Date: May 10, 2012 (54) PROCESS FOR FORMING FILMS, FIBERS, Publication Classification AND BEADS FROM CHITNOUS BOMASS (51) Int. Cl (75) Inventors: Ying Qin, Tuscaloosa, AL (US); AOIN 25/00 (2006.01) Robin D. Rogers, Tuscaloosa, AL A6II 47/36 (2006.01) AL(US); (US) Daniel T. Daly, Tuscaloosa, tish 9.8 (2006.01)C (52) U.S. Cl. ............ 504/358:536/20: 514/777; 426/658 (73) Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF 57 ABSTRACT ALABAMA, Tuscaloosa, AL (US) (57) Disclosed is a process for forming films, fibers, and beads (21) Appl. No.: 13/375,245 comprising a chitinous mass, for example, chitin, chitosan obtained from one or more biomasses. The disclosed process (22) PCT Filed: Jun. 1, 2010 can be used to prepare films, fibers, and beads comprising only polymers, i.e., chitin, obtained from a suitable biomass, (86). PCT No.: PCT/US 10/36904 or the films, fibers, and beads can comprise a mixture of polymers obtained from a suitable biomass and a naturally S3712). (4) (c)(1), Date: Jan. 26, 2012 occurring and/or synthetic polymer. Disclosed herein are the (2), (4) Date: an. AO. films, fibers, and beads obtained from the disclosed process. O O This Abstract is presented solely to aid in searching the sub Related U.S. Application Data ject matter disclosed herein and is not intended to define, (60)60) Provisional applicationpp No. 61/182,833,sy- - - s filed on Jun.
    [Show full text]
  • Association of Oral Anticoagulants and Proton Pump Inhibitor Cotherapy with Hospitalization for Upper Gastrointestinal Tract Bleeding
    Supplementary Online Content Ray WA, Chung CP, Murray KT, et al. Association of oral anticoagulants and proton pump inhibitor cotherapy with hospitalization for upper gastrointestinal tract bleeding. JAMA. doi:10.1001/jama.2018.17242 eAppendix. PPI Co-therapy and Anticoagulant-Related UGI Bleeds This supplementary material has been provided by the authors to give readers additional information about their work. Downloaded From: https://jamanetwork.com/ on 10/02/2021 Appendix: PPI Co-therapy and Anticoagulant-Related UGI Bleeds Table 1A Exclusions: end-stage renal disease Diagnosis or procedure code for dialysis or end-stage renal disease outside of the hospital 28521 – anemia in ckd 5855 – Stage V , ckd 5856 – end stage renal disease V451 – Renal dialysis status V560 – Extracorporeal dialysis V561 – fitting & adjustment of extracorporeal dialysis catheter 99673 – complications due to renal dialysis CPT-4 Procedure Codes 36825 arteriovenous fistula autogenous gr 36830 creation of arteriovenous fistula; 36831 thrombectomy, arteriovenous fistula without revision, autogenous or 36832 revision of an arteriovenous fistula, with or without thrombectomy, 36833 revision, arteriovenous fistula; with thrombectomy, autogenous or nonaut 36834 plastic repair of arteriovenous aneurysm (separate procedure) 36835 insertion of thomas shunt 36838 distal revascularization & interval ligation, upper extremity 36840 insertion mandril 36845 anastomosis mandril 36860 cannula declotting; 36861 cannula declotting; 36870 thrombectomy, percutaneous, arteriovenous
    [Show full text]
  • DOCUMENT RESUME ED 303 441 SP 030 865 TITLE Detection
    DOCUMENT RESUME ED 303 441 SP 030 865 TITLE Detection, Evaluation, and Treatment of High Blood Pressure. Report of the Committee. INSTITUTION National Heart, Lung, and Blood Inst. (DHHS/NIH), Bethesda, MD. PUB DATE 88 NOTE 64p. PUB TYPE Guides - Non-Classroom Use (055) EDRS PRICE MF01/PC03 Plus Postage. DESCRIPTORS *Cardiovascular System; Clinical Diagnosis; *Drug Therapy; *Hypertension; *Pharmacology; Physical Examinations; Physical Health; *Physical Therapy ABSTRACT The availability of an increased variety of therapeutic approaches provides the opportunitl to improve hypertension control while minimizing adverse effects that may influence cardiovascular complications and adherence to therapy. This report serves two purposes: (1) to guide practicing physicians and other health professionals in their care of hypertensive patients; and (2) to guide health professionals participating in the many community high blood pressure control programs. Contents include: (1) definition and prevalence of high blood pressure; (2) detection, confirmation and referral; (3) evaluation and diagnosis; (4) treatment--nonpharmacologic and pharmacologic therapy, and long-term maintenance of therapy; (5) considerations in individual therapy; and (6) special populations and management problems. Fifty-five references are included. (JD) *********************************************************************** Reproductions supplied by EDRS are the best that can be made from the original document. ************************************-*********************************
    [Show full text]
  • Initial Medication Selection for Treatment of Hypertension in an Open-Panel HMO
    J Am Board Fam Pract: first published as 10.3122/jabfm.8.1.1 on 1 January 1995. Downloaded from Initial Medication Selection For Treatment Of Hypertension In An Open-Panel HMO Micky jerome, PharmD, MBA, George C. Xakellis, MD, Greg Angstman, MD, and Wayne Patchin, MBA Background: During the past 25 years recommendations for treating hypertension have evolved from a stepped-care approach to monotherapy or sequential monotherapy as experience has been gained and new antihypertensive agents have been introduced. In an effort to develop a disease management strategy for hypertension, we investigated the prescribing patterns of initial medication therapy for newly treated hypertensive patients. Methods: We examined paid claims data of an open-panel HMO located in the midwest. Charts from 377 patients with newly treated hypertension from a group of 12,242 hypertenSive patients in a health insurance population of 85,066 persons were studied. The type of medication regimen received by patients newly treated for hypertension during an 18-month period was categorized into monotherapy, sequential monotherapy, stepped care, and initial treatment with multiple agents. With monotherapy, the class of medication was also reported. Associations between use of angiotensin-converting enzyme (ACE) inhibitors, calcium channel blockers, or (3-blockers and presence of comorbid conditions were reported. Results: Fifty-five percent of patients received monotherapy, 22 percent received stepped care, and 18 percent received sequential monotherapy. Of those 208 patients receiving monotherapy, 30 percent were prescribed a calcium channel blocker, 22 percent an ACE inhibitor, and 14 percent a f3-blocker. No customization of treatment for comorbid conditions was noted.
    [Show full text]
  • Natural Psychoplastogens As Antidepressant Agents
    molecules Review Natural Psychoplastogens As Antidepressant Agents Jakub Benko 1,2,* and Stanislava Vranková 1 1 Center of Experimental Medicine, Institute of Normal and Pathological Physiology, Slovak Academy of Sciences, 841 04 Bratislava, Slovakia; [email protected] 2 Faculty of Medicine, Comenius University, 813 72 Bratislava, Slovakia * Correspondence: [email protected]; Tel.: +421-948-437-895 Academic Editor: Olga Pecháˇnová Received: 31 December 2019; Accepted: 2 March 2020; Published: 5 March 2020 Abstract: Increasing prevalence and burden of major depressive disorder presents an unavoidable problem for psychiatry. Existing antidepressants exert their effect only after several weeks of continuous treatment. In addition, their serious side effects and ineffectiveness in one-third of patients call for urgent action. Recent advances have given rise to the concept of psychoplastogens. These compounds are capable of fast structural and functional rearrangement of neural networks by targeting mechanisms previously implicated in the development of depression. Furthermore, evidence shows that they exert a potent acute and long-term positive effects, reaching beyond the treatment of psychiatric diseases. Several of them are naturally occurring compounds, such as psilocybin, N,N-dimethyltryptamine, and 7,8-dihydroxyflavone. Their pharmacology and effects in animal and human studies were discussed in this article. Keywords: depression; antidepressants; psychoplastogens; psychedelics; flavonoids 1. Introduction 1.1. Depression Depression is the most common and debilitating mental disease. Its prevalence and burden have been steadily rising in the past decades. For example, in 1990, the World Health Organization (WHO) projected that depression would increase from 4th to 2nd most frequent cause of world-wide disability by 2020 [1].
    [Show full text]
  • Drug and Medication Classification Schedule
    KENTUCKY HORSE RACING COMMISSION UNIFORM DRUG, MEDICATION, AND SUBSTANCE CLASSIFICATION SCHEDULE KHRC 8-020-1 (11/2018) Class A drugs, medications, and substances are those (1) that have the highest potential to influence performance in the equine athlete, regardless of their approval by the United States Food and Drug Administration, or (2) that lack approval by the United States Food and Drug Administration but have pharmacologic effects similar to certain Class B drugs, medications, or substances that are approved by the United States Food and Drug Administration. Acecarbromal Bolasterone Cimaterol Divalproex Fluanisone Acetophenazine Boldione Citalopram Dixyrazine Fludiazepam Adinazolam Brimondine Cllibucaine Donepezil Flunitrazepam Alcuronium Bromazepam Clobazam Dopamine Fluopromazine Alfentanil Bromfenac Clocapramine Doxacurium Fluoresone Almotriptan Bromisovalum Clomethiazole Doxapram Fluoxetine Alphaprodine Bromocriptine Clomipramine Doxazosin Flupenthixol Alpidem Bromperidol Clonazepam Doxefazepam Flupirtine Alprazolam Brotizolam Clorazepate Doxepin Flurazepam Alprenolol Bufexamac Clormecaine Droperidol Fluspirilene Althesin Bupivacaine Clostebol Duloxetine Flutoprazepam Aminorex Buprenorphine Clothiapine Eletriptan Fluvoxamine Amisulpride Buspirone Clotiazepam Enalapril Formebolone Amitriptyline Bupropion Cloxazolam Enciprazine Fosinopril Amobarbital Butabartital Clozapine Endorphins Furzabol Amoxapine Butacaine Cobratoxin Enkephalins Galantamine Amperozide Butalbital Cocaine Ephedrine Gallamine Amphetamine Butanilicaine Codeine
    [Show full text]
  • Long Acting, Reversible Veterinary Sedative and Analgesic And
    University of Kentucky UKnowledge Veterinary Science Faculty Patents Veterinary Science 7-11-2006 Long Acting, Reversible Veterinary Sedative and Analgesic and Method of Use Thomas Tobin University of Kentucky, [email protected] Right click to open a feedback form in a new tab to let us know how this document benefits oy u. Follow this and additional works at: https://uknowledge.uky.edu/gluck_patents Part of the Veterinary Medicine Commons Recommended Citation Tobin, Thomas, "Long Acting, Reversible Veterinary Sedative and Analgesic and Method of Use" (2006). Veterinary Science Faculty Patents. 14. https://uknowledge.uky.edu/gluck_patents/14 This Patent is brought to you for free and open access by the Veterinary Science at UKnowledge. It has been accepted for inclusion in Veterinary Science Faculty Patents by an authorized administrator of UKnowledge. For more information, please contact [email protected]. US007074834B2 (12) United States Patent (10) Patent N0.: US 7,074,834 B2 Tobin (45) Date of Patent: Jul. 11, 2006 (54) LONG ACTING, REVERSIBLE VETERINARY 4,742,054 A 5/1988 Naftchi SEDATIVE AND ANALGESIC AND METHOD 4,950,648 A 8/1990 Raddatz et a1. OF USE 5,635,204 A * 6/1997 GevirtZ et a1. ............ .. 424/449 5,942,241 A 8/1999 Chasin et a1. (75) Inventor: Thomas Tobin, Lexington, KY (US) 5,958,933 A 9/1999 Naftchi (73) Assignee: University of Kentucky Foundation, OTHER PUBLICATIONS Lexington, KY (US) MEDLINE AN 20000025586, Veveris et al, Brit. J. Pharmacol, 128 (5), 1089-97, Nov. 1999, abstract.* ( * ) Notice: Subject to any disclaimer, the term of this Veterinary Pharmacology and Therapeutics, Adams, pp.
    [Show full text]